Impact of National Centralized Drug Procurement policy on chemical pharmaceutical enterprises' R&D investment: a difference-in-differences analysis in China

被引:0
|
作者
Li, Jiaming [1 ]
Zhang, Xinyue [2 ]
Wang, Rui [1 ]
Cao, Keyao [1 ]
Wan, Luhui [1 ]
Ren, Xu [1 ]
Ding, Jinxi [1 ,3 ]
Li, Wei [1 ,3 ]
机构
[1] China Pharmaceut Univ, Sch Int Pharmaceut Business, Nanjing, Peoples R China
[2] Zhejiang Chinese Med Univ, Affiliated Hosp 2, Xinhua Hosp Zhejiang Prov, Hangzhou, Peoples R China
[3] China Pharmaceut Univ, Pharmaceut Market Access Policy Res Ctr, Nanjing, Peoples R China
关键词
National Centralized Drug Procurement policy; chemical pharmaceutical enterprise; R&D investment; influence mechanism; difference-in-difference analysis;
D O I
10.3389/fpubh.2024.1402581
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objective: This study aimed to evaluate the impact of the National Centralized Drug Procurement (NCDP) policy on chemical pharmaceutical enterprises' R&D investment and provide references for improving NCDP policy design and encouraging innovation in the pharmaceutical industry. Methods: Using the panel data of 102 Shanghai and Shenzhen A-share listed enterprises from 2016 to 2022 under the chemical pharmaceutical classification of Shenwan in Wind database as the research sample, this study developed difference-in-differences (DID) models on bid-winning and bid-non-winning enterprises, respectively, to evaluate the impact of NCDP policy on their R&D investment. In addition, this study tested the heterogeneity of bid-winning enterprises based on the bid success rate, the decline of drug price, and enterprise size. Results: The NCDP policy could encourage chemical pharmaceutical companies to increase R&D investment, but the low bid success rate and excessive drug price reduction would reduce their R&D enthusiasm, especially for small- and medium-sized enterprises. Discussion: It is suggested that the NCDP policy should be further improved: first, revise the bidding rule of the NCDP policy and increase the bid success rate so that more enterprises can win bids, and second, to solve the problem of excessive drug price reduction, evaluate the rationality of bid-winning prices, and introduce a two-way selection mechanism between medical institutions and supply enterprises. Integrate pharmacoeconomic evaluation into the NCDP rules to form a benign competition among enterprises. Third, attention should be paid to supporting policies for small- and medium-sized enterprises. By increasing procurement volume, shortening payment time limits, and increasing the proportion of advance payments, enterprises' cash flow shortages can be alleviated, thus achieving fairness and inclusiveness in the implementation of the NCDP policy.
引用
收藏
页数:13
相关论文
共 26 条
  • [1] Influence of Chinese National Centralized Drug Procurement policy on pharmaceutical corporate R&D investment
    Liu, Hang
    Fang, Xinglong
    [J]. APPLIED ECONOMICS, 2024,
  • [2] The impact of national centralized drug procurement on health expenditures for lung cancer inpatients: A difference-in-differences analysis in a large tertiary hospital in China
    Zhang, Yuan-jin
    Ren, Yan
    Zheng, Quan
    Tan, Jing
    Yao, Ming-hong
    Huang, Yun-xiang
    Zhang, Xia
    Zou, Kang
    Zhao, Shao-yang
    Sun, Xin
    [J]. FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [3] Impact of China's National Centralized Drug Procurement Policy on pharmaceutical enterprises' financial performance: a quasi-natural experimental study
    Sun, Zhixuan
    Na, Xin
    Chu, Shuzhen
    [J]. FRONTIERS IN PUBLIC HEALTH, 2023, 11
  • [4] The Impact of the Consistency Evaluation Policy of Generic Drugs on R&D Investment Intensity of Pharmaceutical Companies-An Empirical Study Based on the Difference-in-Differences Model
    Wei, Yanyi
    Zhu, Jialin
    Qiao, Jiahui
    Zhang, Dawei
    Chen, Yuwen
    [J]. FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [5] The impact of US monetary policy on Chinese enterprises' R&D investment
    Zhang Dongyang
    Guo Yumei
    Wang Zhaorui
    Chen Yanbin
    [J]. FINANCE RESEARCH LETTERS, 2020, 35
  • [6] Will the Volume-Based Procurement Policy Promote Pharmaceutical Firms' R&D Investment in China? An Event Study Approach
    Hu, Yuanyuan
    Chen, Shouming
    Qiu, Fangjun
    Chen, Peien
    Chen, Shaoxiong
    [J]. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2021, 18 (22)
  • [7] Impact of China's National Sword Policy on waste import: A difference-in-differences approach
    Lin, Chinho
    Paengsri, Parinyakorn
    Yang, Yiwen
    [J]. ECONOMIC ANALYSIS AND POLICY, 2023, 78 : 887 - 903
  • [8] Impact of National Centralized Drug Procurement Policy on Antiviral Utilization and Expenditure for Hepatitis B in China
    Zhao, Xinyu
    Li, Min
    Wang, Hao
    Xu, Xiaoqian
    Wu, Xiaoning
    Sun, Yameng
    Ning, Canjian
    Wang, Bingqiong
    Chen, Shuyan
    You, Hong
    Jia, Jidong
    Kong, Yuanyuan
    [J]. JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 2022, 10 (03) : 420 - 428
  • [9] Impact of China's National Sword Policy on Waste Import Margins: A Difference-in-Differences Approach
    Li, Bowen
    Mu, Yifei
    [J]. SUSTAINABILITY, 2024, 16 (02)
  • [10] EFFECTS OF MULTIPLE MONETARY POLICY TOOLS ON ENTERPRISES' R&D INVESTMENT: DIFFERENCES AMONG INDUSTRY CATEGORIES
    Dou, Zhenjiang
    Xie, Mengxiang
    Wang, Xiaojun
    [J]. TRANSFORMATIONS IN BUSINESS & ECONOMICS, 2022, 21 (01): : 83 - 100